Frontlight ResearchEarly access
Taking peoplePhase 3
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Key facts
- Who runs it
- CSL Behring
- Where
- United Kingdom1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 90 people, planned
- Started
- 1 Oct 2024
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CSL511 Fibrinogen concentrate (human)
- Cryoprecipitate
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- • Aged >= 18 years at the time of providing written informed consent
- • Diagnosis of PMP requiring CRS with HIPEC
- • Bleeding risk: Predicted intraoperative blood loss of >=2L, assessed within 60 and 100 mins after start of study surgery (assessment made before 2 L of blood is lost)
Who cannot take part
- • Myocardial infarction, acute coronary syndrome, or stroke within 2 months before study surgery
- • Clopidogrel or ticagrelor administration within 5 days before study surgery
- • Prasugrel administration within 7 days before study surgery
- • Oral factor Xa inhibitor administration within 2 days before study surgery
- • Glycoprotein IIb / IIIa antagonist administration within 24 hours before study surgery
- • Oral direct thrombin inhibitor administration within 3 days before study surgery
- • Vitamin K antagonists within 5 days before study surgery
- • Confirmed or suspected congenital or acquired coagulation disorder or a prothrombotic disorder
- • Known history of chronic hepatitis
This trial is currently available in United Kingdom.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.
The 2 groups in the trial
- CSL511Treatment being tested
Treatment: CSL511 Fibrinogen concentrate (human)
- CryoprecipitateExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Single-center, Randomized, Controlled Clinical Study to Investigate the Efficacy of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
- Record updated
- 13 October 2026